Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)

Historic Current Deferred Revenue for SAB Biotherapeutics (SABS) over the last 4 years, with Q3 2024 value amounting to $114698.0.

  • SAB Biotherapeutics' Current Deferred Revenue fell 9295.22% to $114698.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $114698.0, marking a year-over-year decrease of 9295.22%. This contributed to the annual value of $1.3 million for FY2023, which is N/A changed from last year.
  • Per SAB Biotherapeutics' latest filing, its Current Deferred Revenue stood at $114698.0 for Q3 2024, which was down 9295.22% from $114698.0 recorded in Q2 2024.
  • Over the past 5 years, SAB Biotherapeutics' Current Deferred Revenue peaked at $2.9 million during Q1 2023, and registered a low of $100000.0 during Q4 2020.
  • Its 4-year average for Current Deferred Revenue is $1.1 million, with a median of $377835.0 in 2024.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first changed by 0.0% in 2021, then plummeted by 9603.78% in 2024.
  • SAB Biotherapeutics' Current Deferred Revenue (Quarter) stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then skyrocketed by 1222.41% to $1.3 million in 2023, then plummeted by 91.33% to $114698.0 in 2024.
  • Its Current Deferred Revenue was $114698.0 in Q3 2024, compared to $114698.0 in Q2 2024 and $377835.0 in Q1 2024.